GSK_Annual_Report_2021

Notes to the Standalone Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 120 ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 C. Revenue from contracts with customers disaggregated based on geography Revenue from the Country of Domicile- India 3179,10.33 3207,22.07 Revenue from foreign countries 14,63.30 17,45.95 3193,73.63 3224,68.02 D. Reconciliation of gross revenue with revenue from contracts with customers Gross revenue 3391,77.45 3325,23.99 Less: Trade discounts, volume rebates, etc. 231,62.85 137,88.88 Net revenue recognised from contracts with customers 3160,14.60 3187,35.11 Note 28 : Other income Interest income on: Deposits with banks 38,61.66 64,80.21 Income Tax Refund 71,28.52 10,20.62 Loans 16.04 19.36 Others 12.56 2.01 Gain on disposal of Property, Plant and Equipment (net) - 2,33.36 110,18.78 77,55.56 Note 29 : Cost of materials consumed Cost of materials consumed 452,63.87 474,37.97 452,63.87 474,37.97 Note 30 : Changes in inventories of Finished Goods, Stock-in- Trade and Work-In-Progress Opening stock Finished goods 92,38.26 174,06.81 Stock-in-trade 280,02.46 171,54.28 Work-in-progress 30,72.62 22,08.98 403,13.34 367,70.07 Less: Closing stock Finished goods 116,21.99 92,38.26 Stock-in-trade 313,38.13 280,02.46 Work-in-progress 1,06.14 30,72.62 430,66.26 403,13.34 (27,52.92) (35,43.27)